source
- STAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drugThe French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.STAT · 1mo ago↗ source
- 2026 Orphan Drugs Report: A safe(r) passage amid stormy waters?Orphan drugs remain commercially durable, strategically relevant and supported by a strong pipelineBioPharma Dive · 1mo ago↗ source
- Opinion: The military’s medical corps has a serious recruitment problemCongress must incentivize more physicians (and their employers) to join the military medical corps, writes the former attending physician to Congress.STAT · 1mo ago↗ source